<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ciprofloxacin (otic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ciprofloxacin (otic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ciprofloxacin (otic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9050" href="/d/html/9050.html" rel="external">see "Ciprofloxacin (otic): Drug information"</a> and <a class="drug drug_patient" data-topicid="11586" href="/d/html/11586.html" rel="external">see "Ciprofloxacin (otic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F24521178"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cetraxal;</li>
<li>Otiprio [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10821267"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Otic</span>;</li>
<li>
<span class="list-set-name">Antibiotic, Quinolone</span></li></ul></div>
<div class="block dop drugH1Div" id="F9611437"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5d6908b-d92c-483f-9021-2db65a1a0811">Otitis externa, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis externa, acute:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Otic solution 0.2% (Cetraxal): Children and Adolescents: Otic: Instill 0.25 mL (0.5 mg, contents of 1 single-dose container) into affected ear(s) twice daily (approximately 12 hours apart) for 7 days</p>
<p style="text-indent:-2em;margin-left:4em;">Otic suspension 6% (Otiprio): Infants ≥6 months, Children, and Adolescents: Otic: Instill 0.2 mL (12 mg) suspension into each affected ear as a single dose. <b>Note</b>: Intended for administration by health care professional.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a80faaa7-2d63-44f7-9213-45361fa63402">Otitis media with effusion, bilateral</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media with effusion, bilateral:</b> Infants ≥6 months and Children undergoing tympanostomy tube placement: Otic suspension 6% (Otiprio): Intratympanic: Instill 0.1 mL (6 mg) into each affected ear following suctioning of middle ear effusion</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51084792"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosing adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block dohp drugH1Div" id="F51084793"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosing adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doa drugH1Div" id="F9611438"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9050" href="/d/html/9050.html" rel="external">see "Ciprofloxacin (otic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5d6908b-d92c-483f-9021-2db65a1a0811">Otitis externa, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis externa, acute:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Solution 0.2%: <b>Otic:</b> Instill 0.25 mL (0.5 mg) solution (contents of 1 single-dose container) into affected ear twice daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>); may extend an additional 7 days if symptoms are improving but not yet resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24491310']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24491310'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension 6%: <b>Otic:</b> Instill 0.2 mL (12 mg) suspension into affected ear as a single dose.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990509"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doha drugH1Div" id="F50987806"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block adr drugH1Div" id="F9612498"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Irritability (infants and children: 5%), headache (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus of ear (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Fungal superinfection (otic: 2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site pain (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otitis media (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (infants and children: 5%), rhinorrhea (infants and children: 3%)</p></div>
<div class="block coi drugH1Div" id="F9611319"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to ciprofloxacin, other quinolones, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F9611320"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Severe hypersensitivity reactions have occurred with quinolone therapy. Prompt discontinuation of drug should occur if skin rash or other symptoms of hypersensitivity arise.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection. If superinfection occurs, discontinue use and institute appropriate alternative therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tendon inflammation/rupture: There have been reports of tendon inflammation and/or rupture with systemic quinolone antibiotics. Exposure following otic administration is substantially lower than with systemic therapy. Discontinue at first sign of tendon inflammation or pain.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Solution: For otic use only; not for injection, inhalation, or topical ophthalmic use. If infection is not improved after 1 week, consider culture to identify organism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Suspension: For intratympanic (otitis media) and otic (otitis externa) administration.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878770"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In pediatric patients, use of quinolone ear drops after tympanostomy tube placement may increase the risk of tympanic rupture. A retrospective cohort study of over 96,000 patients (&lt;18 years of age) compared patients who received a quinolone-containing ear drop (n=78,275) to those who received a neomycin plus hydrocortisone ear drop (n=18,320). Patients who received quinolone ear drops after tympanostomy tube placement had an increased incidence of tympanic perforation requiring tympanoplasty with an adjusted hazard ratio of 1.61 (95% confidence interval [CI]: 1.15 to 2.26); combination products containing corticosteroids may amplify adverse effect risk; monitor and counsel patients accordingly (Alrwisan 2017)</p></div>
<div class="block foc drugH1Div" id="F9611531"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Otic, as hydrochloride [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cetraxal: 0.2% (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.2% (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Intratympanic [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Otiprio: 6% (1 mL [DSC])</p></div>
<div class="block geq drugH1Div" id="F9611248"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16322775"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Cetraxal Otic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.2% (per each): $52.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ciprofloxacin HCl Otic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.2% (per each): $9.30</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52614446"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Otic:</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis externa, acute:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Otic solution (Cetraxal): For otic use only. Prior to use, warm solution by holding container in hands for at least 1 minute. Patient should lie down with affected ear upward. Patients should remain in the position for at least 1 minute to allow penetration of solution.</p>
<p style="text-indent:-2em;margin-left:4em;">Otic suspension (Otiprio): For otic use; should only be administered by health care professional. Hold vial by aluminum seal to prevent gelation and shake the vial for 5 to 8 seconds until suspension is visually homogenous. Using an 18- to 21-gauge needle, withdraw 0.3 mL from vial into a 1 mL syringe. Prepare second dose for bilateral otitis externa (use separate syringe for each ear), using same vial; vials are single-patient use, discard unused portion. Replace preparation needle with a 20- to 24-gauge, 1.5-inch blunt, flexible catheter (or comparable administration needle/device); a separate administration catheter/needle should be used for each ear. After administration needle/catheter attached to the syringe, prime needle leaving the desired 0.2 mL dose. If gelation occurs during preparation, place vial back in refrigeration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media with effusion, bilateral:</b> Intratympanic: Otic suspension (Otiprio): For intratympanic use only during tympanostomy placement. Hold vial by aluminum seal to prevent gelation and shake vial for 5 to 8 seconds until suspension is visually homogenous. Using an 18- to 21-gauge needle, withdraw 0.3 mL from vial into a 1 mL syringe. Remove needle and attach a 20- to 24-gauge, 2- to 3-inch blunt, flexible catheter/needle to be used for administration. After administration needle/catheter attached, prime needle leaving the desired 0.1 mL dose. Prepare second dose for bilateral otitis media (use separate syringe for each ear and administration catheter/needle), using same vial; vials are single-patient use, discard unused portion. Replace preparation needles with administration needles (separate needles for each ear). If gelation occurs during preparation, place vial back in refrigeration.</p></div>
<div class="block adm drugH1Div" id="F9611470"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Otic solution:</b> For otic use only; not for injection, inhalation, or topical ophthalmic use. Wash hands prior to use. Administer approximately every 12 hours. Prior to use, warm solution by holding container in hands for at least 1 minute. Patient should lie down with affected ear upward and medication instilled. Patients should remain in the position for at least 1 minute to allow penetration of solution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Otic suspension:</b> Refer to manufacturer's product labeling for administration instructions; separate syringes should be used for each ear. Vials are for single-patient use; discard unused portion.</p></div>
<div class="block sts drugH1Div" id="F9611362"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Solution: Store at 15°C to 25°C (59°F to 77°F). Store unused containers in pouch to protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: Store at 2°C to 8°C (36°F to 46°F) in original carton until prior to use to prevent thickening during preparation. Protect from light. If product thickens during preparation, place back in refrigerator. After preparation in a syringe, may store syringe on its side at room temperature or in the refrigerator; discard if not administered in 3 hours.</p></div>
<div class="block usep drugH1Div" id="F53570843"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Cetraxal (0.2 % solution): Treatment of acute otitis externa (FDA approved in ages ≥1 year and adults)</p>
<p style="text-indent:-2em;margin-left:2em;">Otiprio (6% suspension): Treatment of acute otitis externa (FDA approved in ages ≥6 months and adults); intratympanic treatment of bilateral otitis media with effusion in patients undergoing tympanostomy tube placement (FDA approved in pediatric patients ≥6 months)</p></div>
<div class="block mst drugH1Div" id="F9611552"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cetraxal may be confused with cefTRIAXone</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ciprofloxacin may be confused with cephalexin </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299046"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9611341"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F9779657"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Animal reproduction studies have not been conducted with ciprofloxacin otic solution. When administered orally or IV, ciprofloxacin crosses the placenta (Giamarellou 1989; Ludlam 1997). The amount of ciprofloxacin available systemically following topical application of the otic drops is expected to be significantly less in comparison to oral or IV doses. Minimal risk to the fetus and mother is expected following maternal administration.</p></div>
<div class="block pha drugH1Div" id="F9611382"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits DNA-gyrase in susceptible organisms; inhibits relaxation of supercoiled DNA and promotes breakage of double-stranded DNA</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F14721646"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Neofloxin | Raciprox</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ciproxine</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Oxtin | Procif</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Infectocipro</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Ciprenit</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Baycip otico | Cetraflux | Cetraxal | Ciprenit | Ciprofloxacino qualigen | Otociprin | Septocipro otico | Velmonit | Velmonit otico</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cetraxal</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cetraxal | Ciproxin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cetraxal | Cipratic</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cylowam | Ulcori</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Ceflox | Ciprocil | Ciprolar | Cipromac | Ciprox | Swiflox</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cetraflux | Ciproxin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Septocipro otico</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Ciproxina</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cetraxal</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cetraxal</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cipromen | Dv cipro | Hemel | Megacip | Nexcip | Paraflox | Synocip</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ciprofloxacin | Otiprio</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cetraflux | Ciprofloxacina</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cetraxal</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Cetraxal</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Neoxetic</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ciproxina | Oxtin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Ciprobay</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-28329128">
<a name="28329128"></a>Alrwisan A, Antonelli PJ, Winterstein AG. Quinolone ear drops after tympanostomy tubes and the risk of eardrum perforation: a retrospective cohort study. <i>Clin Infect Dis</i>. 2017;64(8):1052-1058.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-otic-pediatric-drug-information/abstract-text/28329128/pubmed" id="28329128" target="_blank">28329128</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cetrexal (ciprofloxacin) [prescribing information]. Ridgeland, MS: WraSer Pharmaceuticals; December 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2589353">
<a name="2589353"></a>Giamarellou H, Kolokythas E, Petrikkos G, et al. "Pharmacokinetics of Three Newer Quinolones in Pregnant and Lactating Women," Ciprofloxacin: major advances in intravenous and oral quinolone therapy. Proceedings of a symposium. April 28 to 29, 1989, Naples, Florida.<i> Am J Med</i>. 1989; 87(5A):49S-51S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-otic-pediatric-drug-information/abstract-text/2589353/pubmed" id="2589353" target="_blank">2589353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9120330">
<a name="9120330"></a>Ludlam H, Wreghitt TG, Thornton S, et al. Q fever in pregnancy. <i>J Infect</i>. 1997;34(1):75-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-otic-pediatric-drug-information/abstract-text/9120330/pubmed" id="9120330" target="_blank">9120330</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Otiprio (ciprofloxacin) [prescribing information]. Port Washington, NY: ALK-Abello Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24491310">
<a name="24491310"></a>Rosenfeld RM, Schwartz SR, Cannon CR, et al. Clinical practice guideline: acute otitis externa. <i>Otolaryngol Head Neck Surg</i>. 2014;150(1 suppl):S1-S24. doi:10.1177/0194599813517083<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-otic-pediatric-drug-information/abstract-text/24491310/pubmed" id="24491310" target="_blank">24491310</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 15952 Version 120.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
